Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07726368 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of ECC4703 With Sulfasalazine and Pitavastatin

StatusRecruiting
PhasePhase 1
SponsorEccogene
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoints added 2 → 8 primary endpoints
See other at-risk trials from Eccogene

Record History

  1. Recruitment opened Start date changed from estimate of Jul 2026 to Aug 7, 2026 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Jul 2026 to Aug 7, 2026
    • Site details revised
  2. Primary endpoint(s) modified Study title shortened, about 2 wordsv2 Show 1 more changeShow less
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eccogene
4 trials monitored
See 2 trials at risk
NASH / MASH
654 trials monitored
See 22 trials at risk
Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis. The overall prevalence of non-alcoholic fatty liver disease is rapidly rising world-wide. ECC4703 is a potential new treatment for non-alcoholic fatty liver disease. The purpose of this research is to investigate the safety, tolerability and pharmacokinetics of sulfasalazine and pitavastatin when combined with ECC4703.
Trial Details
NCT Number NCT07726368
Lead Sponsor Eccogene
Conditions Non-alcoholic Fatty Liver Disease (NAFLD), Dyslipidaemia
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov